Vericel Corp at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Hello, everybody, and welcome. My name is Chris Shibutani. I'm a member of the Goldman Sachs equity research team. We're really pleased that you could join us today. We're very fortunate to have Vericel present for us at our 42nd Annual Goldman Sachs Healthcare Conference.
Certainly, within the whole realm of therapeutic treatments and clinical unmet needs, the notion of addressing severe sports injuries, burn care with cell and tissue therapies has been foundational and been around really for decades. And currently, some of the most advanced generation of therapies which are available clinically and having a real impact are being brought to the fore by Vericel. Here to tell us about the story, Nick Colangelo, President and CEO. Nick, thank you for joining us.
Well, thank you, Chris. It's a pleasure to be here. And before I begin, I would just like to remind the audience that this presentation
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |